BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Company News  |  Deals

Crucell, J&J deal

Johnson & Johnson and Crucell said they are in advanced negotiations for a proposed transaction under which J&J would acquire the remaining 82.1% of the vaccine company it doesn't already own for €24.75 per share, or about €1.8 billion ($2.2 billion) in cash. The price is a...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >